{"id":"lopinavir-ritonavir-4-1","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Abdominal pain"},{"rate":"5-10","effect":"Vomiting"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Hyperglycemia"},{"rate":"10-20","effect":"Lipid abnormalities"},{"rate":"2-5","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL729","moleculeType":"Small molecule","molecularWeight":"628.81"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lopinavir inhibits HIV protease, an enzyme essential for cleaving viral polyproteins into functional components needed for infectious particle assembly. Ritonavir is a potent protease inhibitor that also acts as a pharmacokinetic booster, inhibiting cytochrome P450 metabolism to increase lopinavir plasma concentrations. Together in a 4:1 ratio, they provide synergistic antiviral activity against HIV-1 and HIV-2.","oneSentence":"Lopinavir and ritonavir are HIV protease inhibitors that block the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:55.817Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"},{"name":"HIV-2 infection"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT05334004","phase":"PHASE1","title":"Lopinavir/Ritonavir in PLWH With High-Grade AIN","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-12-19","conditions":"High-Grade Anal Intraepithelial Neoplasia","enrollment":21},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT05914116","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"DualityBio Inc.","startDate":"2023-08-17","conditions":"Advanced Solid Tumors","enrollment":862},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT01513122","phase":"PHASE4","title":"Bone and Body Comp: A Sub Study of the SECOND-LINE Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2010-02","conditions":"HIV","enrollment":210},{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":700},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT05850728","phase":"PHASE1","title":"First in Human Study of TLC-ART 101 (ACTU 2001)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2023-04-01","conditions":"Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy","enrollment":12},{"nctId":"NCT01614405","phase":"NA","title":"Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2012-06","conditions":"Primary Biliary Cirrhosis","enrollment":13},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT00775606","phase":"PHASE4","title":"Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2008-10","conditions":"Acquired Immune Deficiency Syndrome","enrollment":15},{"nctId":"NCT02227238","phase":"PHASE3","title":"Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-12-11","conditions":"HIV Infections","enrollment":627},{"nctId":"NCT04499677","phase":"PHASE2","title":"FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals","status":"COMPLETED","sponsor":"University College, London","startDate":"2020-09-24","conditions":"COVID-19","enrollment":240},{"nctId":"NCT04354428","phase":"PHASE2, PHASE3","title":"Treatment for COVID-19 in High-Risk Adult Outpatients","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-04-16","conditions":"COVID-19, SARS-CoV-2","enrollment":289},{"nctId":"NCT05302947","phase":"","title":"COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU","status":"COMPLETED","sponsor":"Pirogov Russian National Research Medical University","startDate":"2020-02-01","conditions":"COVID-19, Mild to Moderate","enrollment":154},{"nctId":"NCT04394182","phase":"NA","title":"Ultra Low Doses of Therapy With Radiation Applicated to COVID-19","status":"SUSPENDED","sponsor":"Fundacion GenesisCare","startDate":"2020-04-21","conditions":"Pneumonia, Viral, Cytokine Storm","enrollment":15},{"nctId":"NCT01571414","phase":"PHASE1","title":"Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-05","conditions":"Tuberculosis","enrollment":52},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT00086359","phase":"PHASE3","title":"Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-07","conditions":"HIV Infections","enrollment":19},{"nctId":"NCT04303299","phase":"PHASE3","title":"Fight COVID-19 Trial","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2020-08-19","conditions":"SARS-COV-2 Infections, COVID-19","enrollment":320},{"nctId":"NCT04353180","phase":"PHASE3","title":"Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)","status":"UNKNOWN","sponsor":"Kafrelsheikh University","startDate":"2021-08","conditions":"COVID19","enrollment":100000},{"nctId":"NCT01057433","phase":"PHASE4","title":"Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2010-01","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT04365582","phase":"PHASE3","title":"OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome","status":"WITHDRAWN","sponsor":"Fondation Hôpital Saint-Joseph","startDate":"2020-05-07","conditions":"COVID","enrollment":""},{"nctId":"NCT04351724","phase":"PHASE2, PHASE3","title":"Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2020-04-16","conditions":"COVID-19","enrollment":500},{"nctId":"NCT04386876","phase":"PHASE1","title":"Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions","status":"COMPLETED","sponsor":"World Medicine ILAC SAN. ve TIC. A.S.","startDate":"2020-04-30","conditions":"Bioequivalence","enrollment":30},{"nctId":"NCT00679926","phase":"PHASE4","title":"Kaletra and Viread in Antiretroviral Naïve Patients","status":"TERMINATED","sponsor":"Oklahoma State University Center for Health Sciences","startDate":"2008-05","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT00665951","phase":"PHASE1","title":"Pharmacokinetic Study of Two Generic Co-formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2008-09","conditions":"HIV Infections","enrollment":12},{"nctId":"NCT00887120","phase":"PHASE2","title":"Dose Reduction of Lopinavir in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00802334","phase":"PHASE2","title":"TDM of Generic Lopinavir/Ritonavir 200/50 mg","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2008-01","conditions":"HIV","enrollment":70},{"nctId":"NCT04388514","phase":"NA","title":"Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure","status":"UNKNOWN","sponsor":"Azienda Sanitaria-Universitaria Integrata di Udine","startDate":"2020-04-08","conditions":"SARS-CoV-2 Respiratory Failure","enrollment":90},{"nctId":"NCT04374071","phase":"","title":"Early Short Course Corticosteroids in COVID-19","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2020-03-12","conditions":"COVID, Pneumonia, Viral","enrollment":250},{"nctId":"NCT04358614","phase":"PHASE2, PHASE3","title":"Baricitinib Therapy in COVID-19","status":"COMPLETED","sponsor":"Fabrizio Cantini","startDate":"2020-03-16","conditions":"COVID, Pneumonia","enrollment":12},{"nctId":"NCT04320277","phase":"PHASE2, PHASE3","title":"Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.","status":"UNKNOWN","sponsor":"Hospital of Prato","startDate":"2020-05-16","conditions":"Pharmacological Action","enrollment":200},{"nctId":"NCT02415985","phase":"PHASE2","title":"Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2015-06","conditions":"HIV, Tuberculosis","enrollment":40},{"nctId":"NCT03836833","phase":"PHASE1, PHASE2","title":"Lopinavir/r/ Lamivudine/ Abacavir as an Easy to Use Paediatric Formulation","status":"UNKNOWN","sponsor":"Drugs for Neglected Diseases","startDate":"2019-06-04","conditions":"HIV","enrollment":50},{"nctId":"NCT00564772","phase":"PHASE4","title":"Raltegravir Kaletra Pharmacokinetics","status":"COMPLETED","sponsor":"Allina Health System","startDate":"2007-11","conditions":"Healthy","enrollment":15},{"nctId":"NCT01923311","phase":"PHASE2, PHASE3","title":"Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-08-26","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":31},{"nctId":"NCT01601626","phase":"PHASE2","title":"Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-07-13","conditions":"HIV Infection, Tuberculosis","enrollment":71},{"nctId":"NCT00949234","phase":"PHASE2","title":"Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2010-03","conditions":"HIV Prevention, HIV Infections","enrollment":267},{"nctId":"NCT00720590","phase":"NA","title":"Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors","status":"COMPLETED","sponsor":"Indiana University","startDate":"2003-11","conditions":"Endothelial Dysfunction","enrollment":30},{"nctId":"NCT02348177","phase":"PHASE4","title":"Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2013-01","conditions":"Acquired Immunodeficiency Syndrome, Tuberculosis","enrollment":96},{"nctId":"NCT00307151","phase":"PHASE2","title":"Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2005-12","conditions":"HIV Infections","enrollment":452},{"nctId":"NCT02631473","phase":"PHASE1","title":"PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers","status":"SUSPENDED","sponsor":"St Stephens Aids Trust","startDate":"2015-11","conditions":"HIV","enrollment":50},{"nctId":"NCT02157311","phase":"PHASE3","title":"4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-07","conditions":"HIV-1 Infection","enrollment":100},{"nctId":"NCT00771498","phase":"PHASE4","title":"An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin","status":"COMPLETED","sponsor":"Oswaldo Cruz Foundation","startDate":"2008-11","conditions":"HIV Infection, Tuberculosis","enrollment":30},{"nctId":"NCT01294761","phase":"NA","title":"Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir","status":"COMPLETED","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2011-02","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00834457","phase":"PHASE2, PHASE3","title":"A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe","status":"COMPLETED","sponsor":"Parirenyatwa Hospital","startDate":"2007-06","conditions":"AIDS-related Kaposi's Sarcoma","enrollment":49},{"nctId":"NCT00100646","phase":"NA","title":"Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa","status":"COMPLETED","sponsor":"The Wistar Institute","startDate":"2007-03","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00946595","phase":"PHASE2, PHASE3","title":"Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-11","conditions":"HIV Infections","enrollment":420},{"nctId":"NCT00640263","phase":"PHASE3","title":"Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-12","conditions":"HIV Infections","enrollment":1500},{"nctId":"NCT00234091","phase":"PHASE3","title":"When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-04","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00651066","phase":"PHASE2","title":"Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2010-06","conditions":"HIV Infections, Tuberculosis","enrollment":47},{"nctId":"NCT00697892","phase":"PHASE1","title":"Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations","status":"COMPLETED","sponsor":"Fran Aweeka","startDate":"2005-07","conditions":"HIV Infections, Malaria","enrollment":38},{"nctId":"NCT00234975","phase":"PHASE4","title":"Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2002-10","conditions":"HIV Infection","enrollment":86},{"nctId":"NCT00571961","phase":"NA","title":"Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir)","status":"COMPLETED","sponsor":"Yale University","startDate":"2007-01","conditions":"HIV Infections","enrollment":12},{"nctId":"NCT00810108","phase":"PHASE4","title":"Lopinavir/Ritonavir (Kaletra) PK in Children","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2006-06","conditions":"HIV/AIDS Treatment, HIV Infections","enrollment":12},{"nctId":"NCT00573001","phase":"PHASE3","title":"Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2008-07","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00400738","phase":"PHASE2","title":"The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected Patients","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2004-03","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT00772902","phase":"PHASE4","title":"ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-10","conditions":"HIV-1","enrollment":85},{"nctId":"NCT01445223","phase":"PHASE4","title":"A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2004-04","conditions":"HIV","enrollment":242},{"nctId":"NCT00640887","phase":"PHASE2","title":"Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-02","conditions":"HIV Infections, Tuberculosis","enrollment":48},{"nctId":"NCT00525239","phase":"NA","title":"HIV Antiretroviral Drugs and Metabolism","status":"UNKNOWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-03","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT00920088","phase":"PHASE1","title":"Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06","conditions":"Healthy Subjects, Infection, Human Immunodeficiency Virus","enrollment":24},{"nctId":"NCT00743470","phase":"PHASE1","title":"A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects","status":"TERMINATED","sponsor":"Abbott","startDate":"2008-08","conditions":"HIV, Tuberculosis","enrollment":15},{"nctId":"NCT00335192","phase":"PHASE4","title":"To Determine if There Are Pharmacokinetic Interactions at Plasma or Intracellular Level Between Nucleosides and Tenofovir","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-01","conditions":"HIV","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lopinavir/ritonavir"],"phase":"marketed","status":"active","brandName":"Lopinavir/ritonavir 4:1","genericName":"Lopinavir/ritonavir 4:1","companyName":"Drugs for Neglected Diseases","companyId":"drugs-for-neglected-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lopinavir and ritonavir are HIV protease inhibitors that block the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-2 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}